Who is the lecturer invited for this JPI seminar?

The lecturer is Mr. Yasuhiro Araki, Director of the Clinical Trial Promotion Office, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare.

On what date and time is the seminar scheduled to take place?

The seminar is scheduled to take place on Thursday, April 09, 2026, from 09:30 to 11:30.

What does the term "drug loss" refer to according to the lecture overview?

It refers to a problem where medicines approved in Europe and the United States are not developed in Japan, which risks innovative medicines not being provided in Japan.

What are the three goals of the discussions between the public and private sectors in Japan?

The goals are to strengthen Japan's drug discovery capabilities, rapidly deliver the latest medicines to the public, and build a social system where the cycle of investment and innovation is sustained.

AI News NQ Analysis

[JPI Seminar] Ministry of Health, Labour and Welfare "Building a Drug Discovery Ecosystem and Measures to Promote Clinical Trials" to be held on Thursday, April 9th

NQ Score 50/100

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the main title of the seminar to be held by the Japan Planning Institute?: A: The main title is "The Deepening 'Drug Loss' Problem and Strengthening Japan's Drug Discovery Capabilities Ministry of Health, Labour and Welfare: Building a Drug Discovery Ecosystem and Measures to Promote Clinical Trials ~ Regulatory Harmonization and Concrete Measures for the Rapid Delivery of the Latest Medicines ~".
Q: Who is the lecturer invited for this JPI seminar?: A: The lecturer is Mr. Yasuhiro Araki, Director of the Clinical Trial Promotion Office, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare.
Q: On what date and time is the seminar scheduled to take place?: A: The seminar is scheduled to take place on Thursday, April 09, 2026, from 09:30 to 11:30.
Q: What does the term "drug loss" refer to according to the lecture overview?: A: It refers to a problem where medicines approved in Europe and the United States are not developed in Japan, which risks innovative medicines not being provided in Japan.
Q: What are the three goals of the discussions between the public and private sectors in Japan?: A: The goals are to strengthen Japan's drug discovery capabilities, rapidly deliver the latest medicines to the public, and build a social system where the cycle of investment and innovation is sustained.